Combination therapy protects the brain from malaria infection
24 May, 2012 by Tim DeanAdding a new anti-inflammatory drug to conventional malaria treatments may help prevent irrevocable brain damage associated with cerebral malaria.
GTG breast cancer test sales gaining pace in US
22 May, 2012 by Dylan Bushell-EmblingMelbourne's Genetic Technologies (ASX:GTG) has revealed that its genetic test for breast cancer risk, BREVAGen, is gaining traction in the US.
Bioniche developing cancer products for dogs
03 May, 2012 by Dylan Bushell-EmblingBioniche (ASX:BNC) is commercialising two products designed to treat cancer in man's best friend, including an immunotherapy for mammary cancer.
Feature: Skin deep
01 May, 2012 by Fiona WylieSkin cells are constantly generating and differentiating throughout our lives. Professor Fiona Watt is uncovering how stem cells in the skin perform these remarkable feats, and how they can sometimes go awry.
Australian and Israeli researchers team up against obesity
24 April, 2012 by Staff WritersScientists from Israel’s Weizmann Institute of Science will be visiting Australia in May to foster and invest in new collaborations with Australian researchers to tackle obesity.
iSonea to trial wheeze diagnostic in children
29 March, 2012 by Dylan Bushell-EmblingiSonea (ASX:ISN) will conduct a post-market trial of its WheezeoMeter diagnostics tool in patients too young for the traditional spirometry method.
Drug cocktail floors malaria
28 March, 2012 by Tim DeanA combination treatment of anti-malarial drugs given intermittently over 12 months can cut malaria infections by up to 30 per cent in infants.
STAT3 gene highlights delicate immune balance
16 March, 2012 by Tim DeanResearchers have found the STAT3 gene is central to proper immune function, raising hope of new medications to treat immunodeficient and autoimmune disorders.
Feature: Getting drug development right
05 March, 2012 by Graeme O'NeillDrug discovery can be enormously expensive when a drug becomes a disaster. Professor Susan Charman’s team is working to fix potential problems early in the drug-development process.
Genome map sheds light on deadly Tasmanian devil tumour
17 February, 2012 by Tim DeanA new genome map reveals the deadly facial tumour afflicting Tasmanian devils shows some unusual genetic properties.
Lorne 2012: Melanoma treatment blasts off
14 February, 2012 by Tim DeanLorne Cancer: The discovery of a key weakness in metastatic melanoma is a Sputnik moment in the treatment of this deadly cancer. Although Professor Richard Kefford thinks we’re still a long way from landing on the moon.
Lorne 2012: Flipping cancer’s switch
13 February, 2012 by Fiona WylieLorne Protein: Dr Nikki Verrills believes reactivating a suppressed protein phosphatase might just switch off leukaemia cells.
Nominations open for Premier’s Award for Health and Medical Research
10 February, 2012 by Staff WritersThe Victorian Premier’s Award for Health and Medical Research is now open for nominations.
WEHI gets $2m grant for new cancer labs
08 February, 2012 by Tim DeanThe Walter and Eliza Hall Institute (WEHI) has received $2 million from the Australian Cancer Research Foundation (ACRF) to fit out two new cancer research laboratories, which will open in late 2012.
Getting to the heart of microRNAs
06 February, 2012 by Tim DeanA new study reveals the diversity of microRNAs present in the heart, giving some insight into cardiac function and disease.
